International journal of dermatology · 2008
Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Suess Anke, Sticherling Michael
Аннотация
BACKGROUND: Subacute cutaneous lupus erythematosus (SCLE), a distinct clinical subset of lupus erythematosus, remains a therapeutic challenge, especially in cases resistant to topical and standard systemic therapy. Leflunomide, a novel antirheumatic drug, has shown efficacy in the treatment of systemic lupus erythematosus in pilot studies.
METHODS: We report two patients with SCLE who demonstrated the spectrum of possible clinical responses to leflunomide therapy.
RESULTS: One patient experienced a complete clinical remission of symptoms, whereas the other developed a massive skin reaction which was distinctly related to the commencement of leflunomide therapy.
CONCLUSION: To our knowledge, this is the first time that remission and deterioration of SCLE by leflunomide therapy have been described.
METHODS: We report two patients with SCLE who demonstrated the spectrum of possible clinical responses to leflunomide therapy.
RESULTS: One patient experienced a complete clinical remission of symptoms, whereas the other developed a massive skin reaction which was distinctly related to the commencement of leflunomide therapy.
CONCLUSION: To our knowledge, this is the first time that remission and deterioration of SCLE by leflunomide therapy have been described.